Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Provided By GlobeNewswire
Last update: Sep 23, 2024
- Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in Spain and the USA within 21 months –
Read more at globenewswire.comNYSEARCA:TOVX (2/21/2025, 8:04:00 PM)
1.55
-0.06 (-3.73%)
Find more stocks in the Stock Screener
